Lilly Launches New S$42 Million Digital Health Hub in Singapore
Global pharmaceutical company Eli Lilly has announced a significant investment of S$42 million to establish a new Digital Health Innovation Hub in Singapore. This facility is designed to strengthen the country’s position as a leader in medical technology and research.
The new hub will focus on using artificial intelligence (AI) to improve research and development processes. By integrating advanced digital tools, the company aims to speed up the discovery of new medicines and create more efficient healthcare solutions for patients around the world.
Singapore was chosen for this project due to its strong reputation for innovation and its highly skilled workforce in the technology and life sciences sectors. The government has been actively encouraging companies to use AI to solve complex health challenges, making the nation an ideal location for this investment.
This development is expected to create new opportunities for local professionals in the fields of data science and digital health. It also reinforces Singapore's ongoing efforts to become a global center for high-tech medical research and development.